Aliper Alexander M, Frieden-Korovkina Victoria P, Buzdin Anton, Roumiantsev Sergey A, Zhavoronkov Alex
Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Samory Mashela 1, Moscow, 117198, Russia.
Cancer Med. 2014 Aug;3(4):737-46. doi: 10.1002/cam4.239. Epub 2014 Apr 2.
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.
粒细胞集落刺激因子（G-CSF）和粒细胞-巨噬细胞集落刺激因子（GM-CSF）可调节某些实体瘤的进展。分泌G-CSF或GM-CSF的癌症虽然并不常见，但由于细胞因子介导的免疫抑制和血管生成，它们是进展最快的癌症之一。同样，新生血管生成和血管发生可能会使重组G-CSF或GM-CSF的辅助使用复杂化，从而可能导致癌症复发。用于区分分泌G-CSF或GM-CSF癌症的快速诊断工具尚未得到充分发展，因此阻碍了为这些患者制定个体化治疗方案的努力。鉴于辅助性G-/GM-CSF在癌症治疗中的使用越来越多，我们旨在总结最近探索它们在实体瘤病理生理学中作用的研究，并深入了解其治疗应用的一些复杂性。
